Potential Cost-effectiveness of Therapeutic Drug Monitoring for Depressed Patients Treated With Citalopram
Authors:
- Elnaz Ostad HajiEHElnaz Ostad Haji
- Klaus MannKMKlaus Mann
- Aleksandra DragicevicADAleksandra Dragicevic
- Matthias J. MüllerMMMatthias J. Müller
- Katja BolandKBKatja Boland
- Marie-Luise RaoMRMarie-Luise Rao
- Miriam FricMFMiriam Fric
- Gerd LauxGLGerd Laux
- Christoph HiemkeCHChristoph Hiemke
- 1 June 2013
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 35 (3) , 396-401
Abstract
For patients treated with citalopram, it was recently shown that serum concentrations above 50 ng/mL on day 7 of treatment are associated with an improved therapeutic outcome. The aim of this post hoc analysis was to calculate a potential cost-effectiveness of therapeutic drug monitoring (TDM) considering costs for hospitalization, medication, and drug analysis. The study included patients with major depression. Weekly measurements of serum concentrations and assessments of psychopathology were conducted. Fifty-five patients were included in this analysis. For patients with high citalopram serum concentrations (>50 ng/mL), the mean duration of hospitalization was 49 ± 20 days, and it was 72 ± 37 days (P = 0.03) in the group with low drug concentrations (<50 ng/mL). Considering daily costs for hospitalization of 250€,;, the potential savings amounted to 5750€,; per patient for the 23 days. Assuming that 11% of the variation of duration of hospitalization per patient were attributed to the serum concentration of the drug, the resulting savings were 633€,; per patient. Considering the officially listed price of 21€,; per TDM assay, total costs for weekly measurements over a period of 10 weeks of hospitalization were 210€,;. In the groups with high and low serum concentrations, daily costs for citalopram medication were 3.00 ± 0.80€,; and 2.42 ± 0.70€,;, respectively (P = 0.002), and the mean number of comedications was nearly identical, that is, 1.87 ± 1.74 and 1.81 ± 1.86 drugs, respectively (P = 0.919). The data taken together indicate that TDM-guided dosing of citalopram has the potential to be cost effective by reducing the length of hospitalization.Keywords
This publication has 28 references indexed in Scilit:
- Correlation of QTc Interval Prolongation and Serum Level of Citalopram after Intoxication – A Case ReportPharmacopsychiatry, 2011
- Association Between Citalopram Serum Levels and Clinical Improvement of Patients With Major DepressionJournal of Clinical Psychopharmacology, 2011
- Hospitalization for Psychiatric Illness Among Community-Dwelling Elderly Persons in 1992 and 2002Psychiatric Services, 2008
- Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detectionJournal of Chromatography B, 2007
- Cost-Effectiveness of Therapeutic Drug MonitoringTherapeutic Drug Monitoring, 2005
- Therapeutic Drug Monitoring of AntidepressantsClinical Pharmacokinetics, 1999
- Therapeutic Drug Monitoring for the Treatment of Psychiatric DisordersClinical Pharmacokinetics, 1995
- Tricyclic Antidepressant Concentrations in PlasmaJournal of Clinical Psychopharmacology, 1994
- Cost-benefit analysis of prospective pharmacokinetic dosing of nortriptyline in depressed inpatientsJournal of Affective Disorders, 1985
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960